Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies

Rashwan, H.H.; Taher, A.M.; Hassan, H.A.; Awaji, A.A.; Kiriacos, C.J.; Assal, R.A.; Youness, R.A.

doi:10.1016/j.prp.2024.155223

Pathology - Research and Practice

2024

DOI: 10.1016/j.prp.2024.155223

|View full text |Cite

Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies

H.H. Rashwan,

A.M. Taher,

H.A. Hassan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 232 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

miR-17–5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients

Abdelhamid,

Zeinelabdeen,

Manie

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

miR-17–5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients

Abdelhamid,

Zeinelabdeen,

Manie

et al. 2024

Pathology - Research and Practice

View full text Add to dashboard Cite

A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma

Assal,

Elemam,

Mekky

et al. 2024

Translational Oncology

View full text Add to dashboard Cite

New Relevant Evidence in Cholangiocarcinoma Biology and Characterization

Porro,

Spínola-Lasso,

Pastore

et al. 2024

Cancers

View full text Add to dashboard Cite

Among solid tumors, cholangiocarcinoma (CCA) emerges as one of the most difficult to eradicate. The silent and asymptomatic nature of this tumor, particularly in its early stages, as well as the high heterogeneity at genomic, epigenetic, and molecular levels delay the diagnosis, significantly compromising the efficacy of current therapeutic options and thus contributing to a dismal prognosis. Extensive research has been conducted on the molecular pathobiology of CCA, and recent advances have been made in the classification and characterization of new molecular targets. Both targeted therapy and immunotherapy have emerged as effective and safe strategies for various types of cancers, demonstrating potential benefits in advanced CCA. Furthermore, the deeper comprehension of the cellular and molecular components in the tumor microenvironment (TME) has opened up possibilities for new innovative treatment methods. This review discusses recent evidence in the characterization and molecular biology of CCA, highlighting novel possible druggable targets.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Harnessing the supremacy of MEG3 LncRNA to defeat gastrointestinal malignancies

Cited by 4 publications

References 232 publications

miR-17–5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients

miR-17–5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients

A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma

New Relevant Evidence in Cholangiocarcinoma Biology and Characterization

Contact Info

Product

Resources

About